Valuation: VACY AS

Market Cap 112.17Cr 0 12Cr 10Cr 9.59Cr 8.74Cr 16Cr 1.13TCr 17Cr 112.9Cr 44Cr 563.76Cr 44Cr 43Cr 1.88TCr P/E 2026 *
-5.31x
P/E 2027 * -37.1x
Enterprise Value 64Cr 0 6.7Cr 5.8Cr 5.44Cr 4.96Cr 9.34Cr 639.16Cr 9.49Cr 64Cr 25Cr 319.95Cr 25Cr 25Cr 1.07TCr EV / Sales 2026 *
-
EV / Sales 2027 * 3.37x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2019
President 49 01/01/2017
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 23/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 12Cr
+2.07%+13.76%+65.44%+106.53% 7.16TCr
-1.19%-2.33%+33.92%+63.07% 5.44TCr
-4.50%-4.69%+2.82%+463.22% 2.76TCr
-1.27%-1.57%+46.46%+6.09% 2.39TCr
-0.67%+1.02%-18.32%-13.84% 2.31TCr
+0.22%+1.55%+39.18%-19.92% 1.87TCr
+0.35%+12.02%+257.19%+466.50% 1.86TCr
-0.95%-3.52%+20.04%+613.01% 1.6TCr
+0.46%-3.05%+31.49%+135.18% 1.25TCr
Average -0.55%+4.06%+53.14%+202.20% 2.96TCr
Weighted average by Cap. -0.32%+3.63%+50.80%+163.22%

Financials

2026 *2027 *
Net sales - 16Cr 0 1.7Cr 1.47Cr 1.38Cr 1.26Cr 2.37Cr 162.35Cr 2.41Cr 16Cr 6.35Cr 81Cr 6.39Cr 6.25Cr 271.11Cr
Net income -21Cr -0 -2.19Cr -1.9Cr -1.78Cr -1.62Cr -3.05Cr -208.74Cr -3.1Cr -21Cr -8.17Cr -104.49Cr -8.21Cr -8.03Cr -348.57Cr -4.16Cr -0 -43.74L -37.92L -35.54L -32.41L -60.98L -42Cr -61.96L -4.19Cr -1.63Cr -21Cr -1.64Cr -1.61Cr -70Cr
Net Debt -49Cr -0 -5.1Cr -4.42Cr -4.15Cr -3.78Cr -7.11Cr -487.06Cr -7.23Cr -49Cr -19Cr -243.81Cr -19Cr -19Cr -813.33Cr -58Cr -0 -6.08Cr -5.27Cr -4.94Cr -4.5Cr -8.47Cr -579.84Cr -8.61Cr -58Cr -23Cr -290.25Cr -23Cr -22Cr -968.25Cr
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.435NOK
Average target price
5.000NOK
Spread / Average Target
+45.56%

Quarterly revenue - Rate of surprise